
Long-term therapy is necessary for the prevention of relapses of generalized anxiety disorder (GAD), and adherence to it may be hindered by the development of adverse events (AEs). The new domestic drug Aviandr (maritupirdine) has shown efficacy and good tolerability in the treatment of GAD in clinical trials. Objective: to evaluate the safety and tolerability profile of long-term (36-week) GAD therapy with Aviandr (maritupirdine) in real-world clinical practice. Material and methods. An open-label, non-comparative prospective study included 126 patients over 18 years of age with an established diagnosis of GAD. The frequency and severity of AEs, the dynamics of daytime sleepiness on a visual analogue scale (VAS), the presence of with-drawal syndrome, and tolerability features in special patient groups (elderly individuals, patients with somatic comorbidity) were assessed. Results. The vast majority of patients (98.4%) completed the 36-week course of therapy; no patient discontinued the drug due to AEs. Drug-related AEs were registered in 13.49% of patients, predominantly mild in severity (73.1%). The most common AE was somnolence (5.56%), but no clinically significant sedation was noted: the VAS daytime sleepiness score decreased significantly from 39.72±26.29 to 17.73±17.23 by week 36 (p<0.001). No cases of initial worsening of anxiety, sexual dysfunction, weight gain, or Q–T interval prolongation were recorded. No with-drawal syndrome was present 4 weeks after drug discontinuation. In patients aged 65 years and older and in individuals with somatic comorbidity, the safety profile did not differ from the general population. Conclusion. Aviandr demonstrates a high safety and tolerability profile in long-term GAD therapy. The absence of sedation, worsening of anxiety, sexual dysfunction, and withdrawal syndrome ensures high adherence to treatment and makes the drug a safe agent of choice for elderly patients and individuals with concomitant somatic pathology.
The article was prepared by experts of the Russian Headache Society (RHS) and represents an adapted Russian-language version of the International Headache Society (IHS) Global practice recommendations for the treatment of migraine attacks, developed taking into account data from systematic reviews, meta-analyses and consensus documents. The recommendations have two levels: optimal – for countries and regions where most medicines are available, and basic – for regions with limited treatment options. Treatment algorithms using non-steroidal anti-inflammatory drugs, triptans, and gepants are presented, along with specific considerations for their use in special patient groups: pregnant women, the elderly, and patients with cardiovascular diseases. Medicines not registered in the Russian Federation and available alternatives are indicated. The adapted recommendations take into account the Russian specifics of drug availability and the clinical recommendations of the Ministry of Health of Russia. Compliance with the recommendations will improve the quality of care for patients with migraine in the Russian Federation.
Peripheral nervous system (PNS) involvement in antineutrophil cytoplasmic antibody associated vasculitides (ANCA-associated vasculitis) occurs with varying frequency depending on the nosological form. Timely diagnosis and differentiation of PNS involvement phenotypes across different nosological forms are critical for selecting the optimal therapeutic approach. Objective: to develop a diagnostic algorithm for peripheral nervous system (PNS) involvement in ANCA-associated vasculitides and to identify the clinical and electrophysiological characteristics of PNS involvement in granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA). Material and methods. A retrospective-prospective, single-centre cohort study was conducted involving 56 patients with confirmed ANCA-associated vasculitis: GPA (n=22), EGPA (n=21) and MPA (n=13). Clinical neurological examinations were performed using the NIS-LL/UL scales (a scale for the quantitative assessment of neurological deficits in the upper and lower limbs), the DN4 (a diagnostic questionnaire for neuropathic pain), TQOL (Total Quality of Life), electroneuromyography (ENMG) with calculation of asymmetry in parameters, ANCA serological testing, and calculation of the BVAS (Birmingham Vasculitis Activity Score) and VDI (Vasculitis Damage Index). Results. PNS involvement was detected in 100% of the patients examined. GPA was characterized by upper respiratory tract involvement (100%) and hearing loss (59.1%; p=0.002 for paired comparisons versus EGPA and p=0.001 versus MPA), PR3-ANCA (86.4%), a maximum VDI score of 5.50 (5.00–6.75; p=0.010 in a pairwise comparison with MPA), the lowest prevalence of small-fibre neuropathy as determined by quantitative sensory testing (QST; 4.5%) and a reduction in the M-response amplitude of the left median nerve compared with the control group (p<0.001). For EGPA – bronchial asthma (85.7%; paired p<0.001 versus GPA and MPA), ANCA-negativity (47.6%), the highest prevalence of small-fibre neuropathy (57.1%; p=0.001 in pairwise comparisons versus GPA) and the most pronounced changes in temperature thresh-olds according to QST data: an increase in heat sensitivity thresholds and a decrease in cold sensitivity thresholds in dermatomes L5 and S1 compared with the control group (p=0.006 and p=0.001). For MPA – renal involvement (92.3%; paired p=0.017 versus EGPA), the highest proportion of multiple mononeuropathy (53.8% versus 18.2% and 19.0%) and complaints of burning (46.2%), a minimum VDI of 2.00 [2.00; 4.00] and the greatest increase in residual latency of the peroneal nerve compared with the control group (p=0.005). Small-fibre neuropathy in MPA was detected in 30.8% of patients. Asymmetry in EMG parameters >50% was recorded with comparable frequency across all groups (72.7; 71.4 and 76.9%; p=0.909). No differences were found between patient groups in terms of quantitative ENMG and QST parameters (all p>0.05). ANCA-associated vasculitides exhibit specific phenotypes of organ involvement and PNS damage, differing in the nature of the neuropathy and the electrophysiological profile. Based on the data obtained, a multi-stage diagnostic algorithm has been developed, enabling the differentiation of nosological forms and the detection of PNS involvement at the subclinical stage. Conclusion. The multi-stage diagnostic algorithm that has been developed makes it possible to differentiate between forms of ANCA-associated vasculitis based on the nature of the PNS involvement and to detect neuropathy at the subclinical stage.
Epilepsy associated with brain tumors occupies a special place among structural focal epilepsies; it requires a multidisciplinary approach to treatment and close collaboration between a neurologist-epileptologist, a neurosurgeon and an oncologist. Frequent and severe epileptic seizures (including status epilepticus), drug-resistant disease and high mortality rates determine the severity of the condition and the poor quality of life experienced by patients. With the emergence of new and cutting-edge anti-seizure medications (ASMs), it is now a priority to identify the most effective and safest ASMs for the treatment of this patient group. Objective: a retrospective comparative analysis of the efficacy and tolerability of perampanel (PER) as an adjunctive therapy for tumor-associated epilepsies, compared with conventional antiepileptic drugs (AEDs). Material and methods. The study included data from 156 adult patients (aged 19–83) with primary and secondary brain tumors and tumor-associated epilepsy. The patients were divided into two comparable groups of 78 patients each: the main group received antiepileptic therapy including PER, whilst the comparison group received combinations of other AEDs. The follow-up period ranged from 1 year to 3 years or more. Efficacy was assessed after 12 months of treatment in both groups. Results. In the main group, 59% of patients achieved either a one-year seizure remission or a reduction in their frequency of more than 50%, which was significantly higher than the corresponding figure in the comparison group (41%; p=0.014). The incidence of adverse events in the PER group was half that in the control group (10% versus 20%); these events were dose-dependent and did not require discontinuation of the drug. Conclusion. PER has demonstrated high efficacy and a favourable safety profile in tumor-associated epilepsy, which justifies its use in clinical practice for this patient group.
This article addresses a topical issue: the neurological aspects of the diagnosis and management of school maladjustment in children. It examines the main clinical manifestations of school adjustment disorders in children (cognitive, behavioural and asthenic disorders), as well as modern methods for the diagnosis and treatment of these disorders. The high efficacy of the drug Mexidol in the comprehensive management of school adjustment disorders in children is demonstrated.